[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349965-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349965-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","design-and-synthesis-of-peptide-tagged-cubosome-nanocarriers-for-the-targeted-delivery-of-paclitaxel-in-egfr-overexpressing-breast-cancer","Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer","","Targeted delivery of chemotherapeutic agents reduces systemic toxicity and improves therapeutic outcomes by concentrating drug at tumor sites. Lipid-based cubosomal nanocarriers were developed with an optimal size of 157 ± 20 nm to support tumor penetration. The study demonstrates first-time active targeting of cubosomes to EGFR using a short peptide ligand, achieving selective uptake up to 75% in EGFR-overexpressing MDA-MB-468 breast cancer cells while showing minimal uptake in EGFR-negative HEK-293 cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/design-and-synthesis-of-peptide-tagged-cubosome-nanocarriers-for-the-targeted-delivery-of-paclitaxel-in-egfr-overexpressing-breast-cancer/349965/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/design-and-synthesis-of-peptide-tagged-cubosome-nanocarriers-for-the-targeted-delivery-of-paclitaxel-in-egfr-overexpressing-breast-cancer/349965.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the goal of the peptide-tagged cubosome nanocarriers in this study?","Question",{"text":63,"@type":64},"The work aims to actively target EGFR to increase drug accumulation at tumor sites while reducing uptake in EGFR-negative cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the targeted cubosomes evaluated in vitro?",{"text":68,"@type":64},"Selective cellular uptake was measured in EGFR-overexpressing MDA-MB-468 cells and compared with minimal uptake in EGFR-negative HEK-293 cells, followed by viability testing after paclitaxel loading.",{"name":70,"@type":61,"acceptedAnswer":71},"What effects were observed in 3D spheroid and in vivo models?",{"text":72,"@type":64},"In 3D spheroids, survivability decreased markedly in MDA-MB-468 spheroids, while HEK-293 spheroids were largely unaffected. In vivo, targeted treatment suppressed tumor progression without observable liver or kidney toxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349965,1790100673,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","This article is licensed under CC-BY 4.0   \n[pubs.acs.org/journal/abseba](pubs.acs.org/journal/abseba)  Article   \nDesign and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer  \nArindam Pramanik, * Riya Rani, Bhavna Jha, Devlina Das Pramanik, and Prashant Mishra *  \n Cite This: ACS Biomater. Sci. Eng. 2026, 12, 1633−1646  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Targeted delivery of chemotherapeutic agents can reduce systemic toxicity and enhance therapeutic outcomes by increasing the level of drug accumulation at tumor sites. In this study, we developed lipid-based cubosomal nanocarriers with an optimal size of 157 ± 20 nm for effective tumor penetration. This work represents the first demonstration of actively targeting cubosomes to epidermal growth factor receptors (EGFR) using a short peptide ligand. The peptide-functionalized cubosomes exhibited selective uptake of up to 75% in EGFR-overexpressing MDA-MB-468 breast cancer cells while showing minimal uptake (9%) in EGFR-negative HEK-293 cells. Paclitaxel-loaded targeted cubosomes significantly reduced MDA-MB-468 cell viability (47% survival at 60 μg/mL after 24 h) with negligible cytotoxicity in HEK-293 cells (87% survival). In 3D spheroid models, the survivability further decreased to 13% in MDA-MB-468 spheroids after 48 h, whereas HEK-293 spheroids remained largely unaffected. In vivo, targeted treatment suppressed tumor progression, yielding a mean tumor volume of 330 mm3, compared to 675 mm3 and 770 mm3 in untargeted and control groups, respectively, without observable liver or kidney toxicity. These results highlight the therapeutic potential of peptide-tagged cubosomes for the selective treatment of EGFR-expressing cancers.  \nKEYWORDS: cubosomes, 3D tumor spheroids, epidermal growth factor receptor, peptide targeting, in vivo tumor model  \n■ INTRODUCTION  \nLipid-based nanoparticles have emerged as one of the most successful nanocarrier platforms, surpassing many polymeric and metallic systems, with several formulations achieving clinical translation, including Doxil and Amphonex. 1 An emerging class of lyotropic liquid crystalline lipidic nanoparticles also called ‘cubosomes’ has recently gained attention as nanotherapeutics including drug carriers for antimicrobial and cancer therapeutics.2−5 These have interior nanostructures with two- or three-dimensional periodicity, such as hexagonal or cubic symmetry, and are often stabilized by a polymer corona. Compared to conventional liposomes and other nanocarriers, cubosome nanoparticles offer several advantages such as porosity, structural versatility, improved stability, high encapsulation efficiency (due to their greater internal surface area), and biocompatibility as they consist of food-grade materials.5 Their amphiphilic nature allows them to encapsulate both hydrophobic and hydrophilic therapeutics such as nucleic acids (DNA6 and short interfering RNA7), imaging agents,8 and drug molecules.9 Cubosomes also offer a controlled release of drugs, such as in response to pH changes or facilitated cellular uptake. Several chemotherapeutic drug molecules such as paclitaxel,9 methotrexate, 10 doxorubicin, and  \n© 2026 The Authors. Published by American Chemical Society  \ncisplatin2 have been encapsulated in cubosomes and studied for their efficacy in cancer cells. In our recent work, we have specifically delivered cubosomes in colorectal and breast cancer cells using carcinoembryonic antigens and CD44 receptors, respectively, using affimer proteins and hyaluronic acid as ligands. 11, 12  \nAberrant EGFR overexpression drives oncogenesis by promoting uncontrolled growth, angiogenesis, and metastasis.13 EGFR-targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies, have shown clinical benefits.","cbCaismederAfhOs","https://ap.wps.com/l/cbCaismederAfhOs","pdf",15003474,14,"English","# Abstract\n# Keywords\n# Introduction\n## Background on lipid nanoparticles and cubosomes\n## EGFR biology and peptide targeting\n# Materials and Methods\n## Synthesis and peptide tagging","[{\"question\":\"What is the goal of the peptide-tagged cubosome nanocarriers in this study?\",\"answer\":\"The work aims to actively target EGFR to increase drug accumulation at tumor sites while reducing uptake in EGFR-negative cells.\"},{\"question\":\"How were the targeted cubosomes evaluated in vitro?\",\"answer\":\"Selective cellular uptake was measured in EGFR-overexpressing MDA-MB-468 cells and compared with minimal uptake in EGFR-negative HEK-293 cells, followed by viability testing after paclitaxel loading.\"},{\"question\":\"What effects were observed in 3D spheroid and in vivo models?\",\"answer\":\"In 3D spheroids, survivability decreased markedly in MDA-MB-468 spheroids, while HEK-293 spheroids were largely unaffected. In vivo, targeted treatment suppressed tumor progression without observable liver or kidney toxicity.\"}]","Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer | PDF",1790086507,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6865e1ae4f2c1edbde12e686aecf2055.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90235f84a57c68c08722fe91ac20b5ce.webp",982,1295,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dd4fa941aa1c576f6522a5f83245022.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1e812025f9244353af30f4768899750.webp",980,1292]